Jundishapur Journal of Health Sciences

Published by: Kowsar

Analysis of Cardiovascular Diseases Costs and Their Effective Factors in Tabriz Hospitalized Patients, 2015

Ali Imani 1 , Farid Gharibi 2 , * , Ozra Dadashi 3 , Mahdiyeh Najafi 3 and Seyed Mahdi Mirbagheri 4
Authors Information
1 Department of Health Services Management, Iranian Center of Excellence in Health Management (IceHM), School of Health Management and Medical Informatics, Tabriz University of Medical Sciences, Tabriz, IR Iran
2 Department of Health Services Management, Students’ Research Committee, Tabriz University of Medical Sciences, Tabriz, IR Iran
3 Department of Health Services Management, School of Health Management and Medical Informatics, Tabriz University of Medical Sciences, Tabriz, IR Iran
4 Department of Pharmacology, Islamic Azad University, Ahar Branch, Ahar, IR Iran
Article information
  • Jundishapur Journal of Health Sciences: April 01, 2016, 8 (2); e32503
  • Published Online: January 9, 2016
  • Article Type: Research Article
  • Received: August 17, 2015
  • Revised: October 31, 2015
  • Accepted: November 3, 2015
  • DOI: 10.17795/jjhs-32503

To Cite: Imani A, Gharibi F, Dadashi O, Najafi M, Mirbagheri S M. Analysis of Cardiovascular Diseases Costs and Their Effective Factors in Tabriz Hospitalized Patients, 2015, Jundishapur J Health Sci. 2016 ; 8(2):e32503. doi: 10.17795/jjhs-32503.

Copyright © 2016, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Rosen VM, Taylor DC, Parekh H, Pandya A, Thompson D, Kuznik A, et al. Cost effectiveness of intensive lipid-lowering treatment for patients with congestive heart failure and coronary heart disease in the US. Pharmacoeconomics. 2010; 28(1): 47-60[DOI][PubMed]
  • 2. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ, Comparative Risk Assessment Collaborating G. Selected major risk factors and global and regional burden of disease. Lancet. 2002; 360(9343): 1347-60[DOI][PubMed]
  • 3. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003; 326(7404): 1419[DOI][PubMed]
  • 4. Mason H, Shoaibi A, Ghandour R, O'Flaherty M, Capewell S, Khatib R, et al. A cost effectiveness analysis of salt reduction policies to reduce coronary heart disease in four Eastern Mediterranean countries. PLoS One. 2014; 9(1)[DOI][PubMed]
  • 5. Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. Growing epidemic of coronary heart disease in low- and middle-income countries. Curr Probl Cardiol. 2010; 35(2): 72-115[DOI][PubMed]
  • 6. Hatmi ZN, Tahvildari S, Gafarzadeh Motlag A, Sabouri Kashani A. Prevalence of coronary artery disease risk factors in Iran: a population based survey. BMC Cardiovasc Disord. 2007; 7: 32[DOI][PubMed]
  • 7. Rastegarpanah M, Malekzadeh F, Thomas GN, Mohagheghi A, Cheng KK, Marshall T. A new horizon in primary prevention of cardiovascular disease, can we prevent heart attack by "heart polypill"? Arch Iran Med. 2008; 11(3): 306-13[PubMed]
  • 8. Namazi MH, Mohagheghi A, Ostovaneh MR. Prevention of cardiovascular diseases in developing countries. Arch Iran Med. 2012; 15(9): 528-30[PubMed]
  • 9. Zheng H, Ehrlich F, Amin J. Economic evaluation of the direct healthcare cost savings resulting from the use of walking interventions to prevent coronary heart disease in Australia. Int J Health Care Finance Econ. 2010; 10(2): 187-201[DOI][PubMed]
  • 10. Begg SJ, Vos T, Barker B, Stanley L, Lopez AD. Burden of disease and injury in Australia in the new millennium: measuring health loss from diseases, injuries and risk factors. Med J Aust. 2008; 188(1): 36-40[PubMed]
  • 11. Cobiac LJ, Magnus A, Barendregt JJ, Carter R, Vos T. Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study. BMC Public Health. 2012; 12: 398[DOI][PubMed]
  • 12. McMurray JJV, Pfeffer MA. Heart failure. The Lancet. 2005; 365(9474): 1877-89[DOI]
  • 13. Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail. 2002; 4(3): 361-71[PubMed]
  • 14. Seo HY, Yoon SJ, Kim EJ, Oh IH, Lee YH, Kim YA. The economic burden of rheumatic heart disease in South Korea. Rheumatol Int. 2013; 33(6): 1505-10[DOI][PubMed]
  • 15. Imani A, Ahmadipoor S, Jannati A, Gholipour K, Ghoddoosi-Nejad J. Analysis and estimation of the direct and indirect costs of breast cancer in women attending Shahid Ghazi clinic, Tabriz, 2013 [In Persian]. Depict Health. 2014; 5(3): 13-9
  • 16. Mourad G, Alwin J, Stromberg A, Jaarsma T. Societal costs of non-cardiac chest pain compared with ischemic heart disease--a longitudinal study. BMC Health Serv Res. 2013; 13: 403[DOI][PubMed]
  • 17. Hajizadeh E, Asghari M. Statistical methods and analyses in health biosciences [In Persian]. 2010; : 397-422
  • 18. Yaghmale F. Content validity and its estimation. J Med Educ. 2003; 3(1): 25-7
  • 19. Goss JR. 2008;
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments